A Sequentially Priming Phosphorylation Cascade Activates the Gliomagenic Transcription Factor Olig2.

PubWeight™: 0.80‹?›

🔗 View Article (PMID 28355568)

Published in Cell Rep on March 28, 2017

Authors

Jing Zhou1, An-Chi Tien2, John A Alberta1, Scott B Ficarro3, Amelie Griveau2, Yu Sun1, Janhavee S Deshpande4, Joseph D Card4, Meghan Morgan-Smith5, Wojciech Michowski6, Rintaro Hashizume7, C David James7, Keith L Ligon8, William D Snider5, Peter Sicinski6, Jarrod A Marto9, David H Rowitch10, Charles D Stiles11

Author Affiliations

1: Department of Neurobiology, Harvard Medical School, Boston, MA 02115, USA; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
2: Departments of Pediatrics and Neurosurgery, University of California, San Francisco, 35 Medical Center Way, San Francisco, CA 94143, USA.
3: Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA; Blais Proteomics Center, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
4: Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
5: UNC Neuroscience Center, University of North Carolina, Chapel Hill, NC 27599, USA.
6: Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Genetics, Harvard Medical School, Boston, MA 02115, USA.
7: Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, 300 E. Superior, Chicago, IL 60611, USA.
8: Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
9: Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Blais Proteomics Center, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
10: Departments of Pediatrics and Neurosurgery, University of California, San Francisco, 35 Medical Center Way, San Francisco, CA 94143, USA; Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, University of California, San Francisco, 35 Medical Center Way, San Francisco, CA 94143, USA; Department of Pediatrics, University of Cambridge, Wellcome Trust-MRC Cambridge Stem Cell Institute, Cambridge CB2 0AH, UK. Electronic address: rowitchd@peds.ucsf.edu.
11: Department of Neurobiology, Harvard Medical School, Boston, MA 02115, USA; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA. Electronic address: charles_stiles@dfci.harvard.edu.

Articles cited by this

Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature (2008) 75.40

Identification of a cancer stem cell in human brain tumors. Cancer Res (2003) 24.02

Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res (2004) 14.73

Role of the INK4a locus in tumor suppression and cell mortality. Cell (1996) 11.41

GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci (2003) 10.89

Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci U S A (2003) 10.56

Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature (2000) 8.37

One-thousand-and-one substrates of protein kinase CK2? FASEB J (2003) 6.89

Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro. Glia (2002) 5.81

Common developmental requirement for Olig function indicates a motor neuron/oligodendrocyte connection. Cell (2002) 5.64

The bHLH transcription factors OLIG2 and OLIG1 couple neuronal and glial subtype specification. Cell (2002) 5.35

Protein kinase CK2: structure, regulation and role in cellular decisions of life and death. Biochem J (2003) 5.11

A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes Dev (2007) 5.07

Acquisition of granule neuron precursor identity is a critical determinant of progenitor cell competence to form Shh-induced medulloblastoma. Cancer Cell (2008) 4.68

Olig2-regulated lineage-restricted pathway controls replication competence in neural stem cells and malignant glioma. Neuron (2007) 4.47

Cdk1 is sufficient to drive the mammalian cell cycle. Nature (2007) 4.26

Reconstructing and reprogramming the tumor-propagating potential of glioblastoma stem-like cells. Cell (2014) 4.04

Cdk2 knockout mice are viable. Curr Biol (2003) 3.92

The acidic transcriptional activation domains of VP16 and p53 bind the cellular replication protein A and stimulate in vitro BPV-1 DNA replication. Cell (1993) 3.68

Transcriptional activation. Acid blobs and negative noodles. Nature (1988) 3.24

Chemical genetic screen for AMPKα2 substrates uncovers a network of proteins involved in mitosis. Mol Cell (2011) 2.99

The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas. J Neuropathol Exp Neurol (2004) 2.66

Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. Cancer Res (2010) 2.56

Glycogen synthase kinase 3alpha-specific regulation of murine hepatic glycogen metabolism. Cell Metab (2007) 2.12

GSK-3 is a master regulator of neural progenitor homeostasis. Nat Neurosci (2009) 2.11

Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties. ACS Chem Neurosci (2010) 2.06

Tissue-specific role of glycogen synthase kinase 3beta in glucose homeostasis and insulin action. Mol Cell Biol (2008) 2.03

The central nervous system-restricted transcription factor Olig2 opposes p53 responses to genotoxic damage in neural progenitors and malignant glioma. Cancer Cell (2011) 1.92

Phosphorylation state of Olig2 regulates proliferation of neural progenitors. Neuron (2011) 1.83

A crucial role for Olig2 in white matter astrocyte development. Development (2007) 1.60

Nuclear factor of activated T cells (NFAT)-dependent transactivation regulated by the coactivators p300/CREB-binding protein (CBP). J Exp Med (1998) 1.58

Oligodendrocyte lineage genes (OLIG) as molecular markers for human glial brain tumors. Proc Natl Acad Sci U S A (2001) 1.29

A human brainstem glioma xenograft model enabled for bioluminescence imaging. J Neurooncol (2009) 1.26

Separated at birth? The functional and molecular divergence of OLIG1 and OLIG2. Nat Rev Neurosci (2012) 1.22

Switching Cdk2 on or off with small molecules to reveal requirements in human cell proliferation. Mol Cell (2011) 1.21

OLIG2 as a specific marker of oligodendroglial tumour cells. Lancet (2001) 1.19

Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy. Proc Natl Acad Sci U S A (2012) 1.15

Targeting protein kinase CK2 suppresses prosurvival signaling pathways and growth of glioblastoma. Clin Cancer Res (2013) 1.13

Inhibition of Casein kinase-2 induces p53-dependent cell cycle arrest and sensitizes glioblastoma cells to tumor necrosis factor (TNFα)-induced apoptosis through SIRT1 inhibition. Cell Death Dis (2012) 1.10

Shared oligodendrocyte lineage gene expression in gliomas and oligodendrocyte progenitor cells. J Neurosurg (2003) 1.09

Current Understanding of BRAF Alterations in Diagnosis, Prognosis, and Therapeutic Targeting in Pediatric Low-Grade Gliomas. Front Oncol (2015) 1.02

Inhibition of p53 DNA binding function by the MDM2 protein acidic domain. J Biol Chem (2011) 0.99

The acidic C-terminal domain and A-box of HMGB-1 regulates p53-mediated transcription. Nucleic Acids Res (2003) 0.96

Expression of the oligodendroglial lineage-associated markers Olig1 and Olig2 in different types of human gliomas. J Neuropathol Exp Neurol (2003) 0.95

Disruption of CK2beta in embryonic neural stem cells compromises proliferation and oligodendrogenesis in the mouse telencephalon. Mol Cell Biol (2010) 0.93

The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment of human hematological malignancies. Front Pharmacol (2015) 0.92

Post-translational Modifications of OLIG2 Regulate Glioma Invasion through the TGF-β Pathway. Cell Rep (2016) 0.87

Pediatric low-grade gliomas: how modern biology reshapes the clinical field. Biochim Biophys Acta (2014) 0.86

Casein kinase 2α regulates glioblastoma brain tumor-initiating cell growth through the β-catenin pathway. Oncogene (2014) 0.82